Guggenheim analyst Yatin Suneja raised the firm’s price target on AnaptysBio (ANAB) to $54 from $52 and keeps a Buy rating on the shares. Following Q1 earnings, the firm says it is “encouraged by the company’s clinical development and its robust pipeline.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Hold Rating for AnaptysBio Amid Uncertainties in Clinical Trial Data and Market Position
- AnaptysBio reports Q1 EPS ($1.28), consensus ($1.46)
- Promising Financial Future for AnaptysBio: Buy Rating Justified by Strategic Collaborations and Market Performance
- AnaptysBio could have positive read from J&J abstracts, says Guggenheim
- AnaptysBio board authorizes $75M stock repurchase plan